These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Smitherman TC; Milam M; Woo J; Willerson JT; Frenkel EP Am J Cardiol; 1981 Sep; 48(3):395-402. PubMed ID: 6168192 [No Abstract] [Full Text] [Related]
24. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator]. Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348 [TBL] [Abstract][Full Text] [Related]
25. Streptokinase or tissue plasminogen activator and left ventricular function after myocardial infarction. N Engl J Med; 1989 Sep; 321(10):687-9. PubMed ID: 2505074 [No Abstract] [Full Text] [Related]
26. Impact of different reperfusion modalities on ventricular function after acute myocardial infarction. O'Neill WW Am J Cardiol; 1988 May; 61(14):45G-53G. PubMed ID: 2966565 [TBL] [Abstract][Full Text] [Related]
27. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. Serebruany VL; Malinin AI; Callahan KP; Binbrek A; Van De Werf F; Alexander JH; Granger CB; Gurbel PA; Am Heart J; 2003 Apr; 145(4):636-42. PubMed ID: 12679759 [TBL] [Abstract][Full Text] [Related]
28. Primary coronary angioplasty versus thrombolysis for acute myocardial infarction. Fresco C Lancet; 2003 Apr; 361(9365):1303; author reply 1304-5. PubMed ID: 12699989 [No Abstract] [Full Text] [Related]
29. Possible interaction of platelets and adrenaline in the early phase of myocardial infarction. Seitz R; Leising H; Liebermann A; Rohner I; Gerdes H; Egbring R Res Exp Med (Berl); 1987; 187(5):385-93. PubMed ID: 2963360 [TBL] [Abstract][Full Text] [Related]
30. Use of tissue plasminogen activator in the coronary care unit for acute closure after coronary angioplasty. Alzarka A; Haft JI; Goldstein JE Chest; 1990 May; 97(5):1241-2. PubMed ID: 2110053 [TBL] [Abstract][Full Text] [Related]
31. Differential effect of platelets on plasminogen activation by tissue plasminogen activator, urokinase, and streptokinase. Gao SW; Morser J; McLean K; Shuman MA Thromb Res; 1990 May; 58(4):421-33. PubMed ID: 2112791 [TBL] [Abstract][Full Text] [Related]
32. Delayed coronary angioplasty after thrombolytic therapy for acute myocardial infarction. Little T; Lee K; Mukherjee D; Milner M; Lindsay J; Pichard AD Am J Cardiol; 1990 Nov; 66(17):1259-60. PubMed ID: 2122706 [No Abstract] [Full Text] [Related]
33. The rt-PA versus streptokinase. Controversy--I. Lenfant C J Am Coll Cardiol; 1992 Apr; 19(5):1116. PubMed ID: 1348064 [No Abstract] [Full Text] [Related]
34. Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator. Peuhkurinen K; Risteli L; Jounela A; Risteli J Am Heart J; 1996 Jan; 131(1):7-13. PubMed ID: 8554022 [TBL] [Abstract][Full Text] [Related]
35. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups. Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990 [TBL] [Abstract][Full Text] [Related]
36. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Berger PB; Holmes DR; Stebbins AL; Bates ER; Califf RM; Topol EJ Circulation; 1997 Jul; 96(1):122-7. PubMed ID: 9236426 [TBL] [Abstract][Full Text] [Related]
37. Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. Labinaz M; Sketch MH; Stebbins AL; DeFranco AC; Holmes DR; Kleiman NS; Betriu A; Rutsch WR; Vahanian A; Topol EJ; Califf RM Am J Cardiol; 1996 Dec; 78(12):1338-44. PubMed ID: 8970403 [TBL] [Abstract][Full Text] [Related]
38. Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Pilote L; Califf RM; Sapp S; Miller DP; Mark DB; Weaver WD; Gore JM; Armstrong PW; Ohman EM; Topol EJ N Engl J Med; 1995 Aug; 333(9):565-72. PubMed ID: 7623907 [TBL] [Abstract][Full Text] [Related]